Table 1. Patient Characteristics.
| Chemotherapy | Chemotherapy plus icotinib | |
|---|---|---|
| (n = 18) | (n = 21) | |
| n (%) | n (%) | |
| Age | ||
| 55.50 ± 9.74 | 57.29 ± 10.88 | |
| Gender | ||
| Male | 11 (61.1) | 16 (76.2) |
| Female | 7 (38.9) | 5 (23.8) |
| Maximum diameter of tumor (cm) | ||
| 3.91 ± 1.53 | 3.51 ± 1.74 | |
| Histology | ||
| Adenocarcinoma | 17 (94.4) | 20 (95.2) |
| Squamous cell carcinoma | 1 (5.6) | 1 (4.8) |
| Smoking status | ||
| Present or former smoker | 10 (55.6) | 10 (47.6) |
| Non-smoker | 8 (44.4) | 11 (52.4) |
| Lymph node status | ||
| N0 | 11 (61.1) | 12 (57.1) |
| N1 | 3 (16.7) | 1 (4.8) |
| N2 | 4 (22.2) | 8 (38.1) |
| Tumor differentiation | ||
| Well | 9 (50.0) | 10 (47.6) |
| Moderate or Poor | 9 (50.0) | 11 (52.4) |
| pTMN stage | ||
| I B high-risk patients a | 8 (44.4) | 9 (42.9) |
| Ⅱ | 5 (27.8) | 5 (23.8) |
| ⅢA | 5 (27.8) | 7 (33.3) |
| EGFR mutations | ||
| 19delete | 7(38.9%) | 9(42.9%) |
| 21 L858R | 10(55.6%) | 12(57.1%) |
| Other | 1(5.6%) | 0 |
a High-risk patients were defined as patients with poorly differentiated tumors (including lung neuroendocrine tumors, but excluding well-differentiated neuroendocrine tumors), vascular invasion, wedge resection, tumor size > 4 cm, visceral pleural involvement or incomplete lymph node sampling.